# Psychedelic-Assisted Therapy for Mental Health Disorders: A Comprehensive Meta-Analytic Synthesis Contrasting Efficacy Against Conventional Pharmacotherapy and Psychotherapy

---

**Authors:** Synthesized review (AI-assisted)
**Date:** February 2026 (Expanded Edition)
**Keywords:** psilocybin, MDMA, LSD, DMT, ayahuasca, ibogaine, ketamine, depression, PTSD, substance use disorder, obsessive-compulsive disorder, eating disorders, cluster headache, meta-analysis, serotonin, 5-HT2A, default mode network, neuroplasticity, psychoplastogens, cost-effectiveness

---

## Abstract

Psychedelic-assisted therapy has re-emerged as one of the most actively investigated paradigms in psychiatric research. This expanded synthesis integrates findings from systematic reviews, meta-analyses, pivotal clinical trials, and long-term follow-up studies examining the efficacy of classic serotonergic psychedelics (psilocybin, LSD, DMT, ayahuasca), MDMA (3,4-methylenedioxymethamphetamine), ibogaine, and ketamine/esketamine across major depressive disorder (MDD), treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), substance use disorders (SUDs), obsessive-compulsive disorder (OCD), cancer-related existential distress, eating disorders, and cluster headache. Effect sizes are benchmarked against both inert/active placebo controls and the full spectrum of conventional first-line interventions: SSRIs, SNRIs, trauma-focused psychotherapy (PE, CPT, EMDR), anti-craving medications (naltrexone, acamprosate), and smoking cessation pharmacotherapy (varenicline, NRT, bupropion).

We examine the neurobiological mechanisms of action — centering on 5-HT2A receptor agonism, default mode network (DMN) modulation, and psychoplastogen-mediated neuroplasticity — and provide critical appraisal of safety data, cost-effectiveness analyses, the international regulatory landscape, and equity considerations. The converging evidence indicates large acute treatment effect sizes for psilocybin in depression (Hedges' g = -0.66 to -1.49 across meta-analyses), for MDMA-assisted therapy in PTSD (Cohen's d = 0.7–0.91), and emerging signals for LSD in anxiety (d = -1.18), DMT in depression (MADRS difference = -7.35 vs. placebo), and psilocybin in substance use disorders. These effect magnitudes consistently exceed those of SSRIs (g ≈ 0.30) and are comparable to or exceed gold-standard psychotherapy. However, methodological limitations — including functional unblinding, high risk of bias, modest Phase 3 MADRS deltas (-3.6 to -3.8 points for COMP360), the FDA's 2024 rejection of MDMA for PTSD, and the retraction of key MDMA long-term follow-up data — underscore the need for larger, more rigorous confirmatory trials before these interventions can be integrated into standard psychiatric care. Critically, these limitations must be interpreted within their historical context: the approximately 35-year moratorium on psychedelic research (1970–2006) was not precipitated by scientific evidence of harm or therapeutic futility, but by politically motivated scheduling decisions — most notably the Nixon administration's deployment of the Controlled Substances Act to suppress domestic dissent during the Vietnam War era (Baum, 2016). The placement of psilocybin, LSD, and MDMA in Schedule I alongside heroin — a classification denoting "no accepted medical use" and "high potential for abuse" — persists despite independent harm analyses ranking these substances well below alcohol, tobacco, and other legal drugs (Nutt et al., 2010). The resulting decades-long research prohibition, compounded by the financial disincentives facing a pharmaceutical industry structured around daily-dose patent-protected medications, means that the current evidence base is effectively rebuilding from a politically imposed ground zero rather than reflecting an inherent lack of therapeutic promise.

---

## 1. Introduction

### 1.1 The Burden of Treatment-Resistant Mental Illness

Major depressive disorder affects over 280 million people globally and is the leading cause of disability worldwide (WHO, 2023). Post-traumatic stress disorder has an estimated lifetime prevalence of approximately 3.9% globally, with substantially higher rates among military veterans, refugees, and survivors of sexual violence. Drug use disorders alone account for nearly 500,000 deaths annually, with alcohol-attributable mortality adding approximately 2.6 million more (WHO, 2024). Obsessive-compulsive disorder affects 1–3% of the global population, with approximately 40–60% of patients failing to achieve adequate response to first-line serotonergic pharmacotherapy.

Despite decades of pharmacological development, treatment outcomes remain unsatisfactory for a significant proportion of patients. Approximately 30% of individuals with MDD do not respond adequately to two or more trials of antidepressant medication, meeting criteria for treatment-resistant depression (Rush et al., 2006). First-line SSRIs typically show modest effect sizes (Cohen's d ≈ 0.30 vs. placebo) and require 4–8 weeks to achieve full therapeutic effect (Cipriani et al., 2018). Publication bias inflates the apparent efficacy of antidepressants: Turner et al. (2008) demonstrated that when unpublished FDA-registered trial data are included, the aggregate effect size for 12 antidepressant drugs is 32% smaller than published literature suggests, with 94% of published trials appearing positive compared to only 51% per FDA records. For PTSD, only two medications — sertraline and paroxetine — hold FDA approval, with effect sizes that are similarly modest (d ≈ 0.3–0.4) and remission rates below 30% (Stein et al., 2006). These limitations have catalyzed a search for mechanistically novel interventions.

### 1.2 The Psychedelic Renaissance

Classic serotonergic psychedelics — including psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), and DMT (N,N-dimethyltryptamine) — were investigated extensively in the 1950s and 1960s for conditions spanning alcoholism, depression, and end-of-life anxiety. An estimated 40,000 patients received psychedelic therapy before the Controlled Substances Act of 1970 effectively halted research (Dyck, 2005). The modern resurgence, beginning with Moreno et al. (2006) for OCD and Griffiths et al. (2006) for psilocybin-occasioned mystical experiences, has produced a rapidly growing body of randomized controlled trial (RCT) evidence spanning depression, PTSD, substance use disorders, cancer-related distress, anxiety disorders, eating disorders, and headache conditions.

MDMA, a substituted amphetamine with combined serotonergic, dopaminergic, and noradrenergic activity, occupies a distinct pharmacological niche. It is classified as an "entactogen" rather than a classic psychedelic and has been investigated primarily for PTSD, where its prosocial and fear-extinction-enhancing properties are hypothesized to facilitate trauma processing within a therapeutic relationship.

### 1.3 The Political Suppression of Psychedelic Research

The current paucity of large-scale, Phase 3 psychedelic trial data is not an organic consequence of failed science but the direct product of a politically engineered research moratorium that lasted approximately 35 years (1970–2006). Understanding this history is essential for interpreting the present evidence base and its limitations.

#### 1.3.1 The First Wave: European and North American Research (1950s–1960s)

Psychedelic research originated not as a countercultural phenomenon but as mainstream psychiatry. Beginning in the 1950s, LSD was investigated in over 1,000 clinical studies across Europe and North America (Rucker et al., 2018). Czechoslovak psychiatrist Stanislav Grof conducted some of the most extensive clinical work, administering LSD to over 4,000 sessions and documenting its application in depression, addiction, and psychosomatic conditions (Grof, 1975). In Saskatchewan, Canada, Humphry Osmond — who coined the term "psychedelic" — and Abram Hoffer conducted pioneering trials of LSD for alcoholism, reporting recovery rates substantially exceeding those of conventional treatment (Dyck, 2005). British psychiatrist Ronald Sandison established the first dedicated LSD therapy clinic in Europe at Powick Hospital in 1953, treating neurotic and psychosomatic patients within a psycholytic (low-dose, repeated) framework that was distinct from the North American psychedelic (high-dose, single session) model (Sessa, 2012). An estimated 40,000 patients received psychedelic-assisted therapy during this period, and six international scientific conferences on LSD therapy were held between 1950 and 1965.

This first wave produced a substantial — if methodologically imperfect by modern standards — evidence base suggesting therapeutic utility across multiple psychiatric conditions. Its termination was not precipitated by scientific findings of inefficacy or unacceptable harm.

#### 1.3.2 The Controlled Substances Act and the Politicization of Drug Scheduling

The passage of the Controlled Substances Act (CSA) in 1970 and the subsequent placement of psychedelics in Schedule I effectively criminalized not only recreational use but also clinical research. The political motivations behind this action were made explicit decades later by John Ehrlichman, domestic policy advisor to President Richard Nixon, in a 2016 interview published in *Harper's Magazine*:

> "The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. You understand what I'm saying? We knew we couldn't make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities. We could arrest their leaders, raid their homes, break up their meetings, and vilify them night after night on the evening news. Did we know we were lying about the drugs? Of course we did." (Baum, 2016)

While the veracity and context of this statement have been debated by Ehrlichman's surviving family, it is consistent with the documented legislative record. The CSA's scheduling criteria — requiring assessment of "actual or relative potential for abuse," "scientific evidence of its pharmacological effect," and "state of current scientific knowledge" — were applied to psychedelics in a manner that disregarded the existing clinical literature. Schedule I classification designates a substance as having "high potential for abuse" and "no currently accepted medical use," placing psilocybin and LSD in the same category as heroin while leaving alcohol and tobacco — substances responsible for orders of magnitude more morbidity and mortality — entirely unscheduled.

#### 1.3.3 The Empirical Case Against Current Scheduling

The disconnect between drug scheduling and evidence-based harm assessment has been documented rigorously. Nutt et al. (2010), in a landmark analysis published in *The Lancet*, convened an expert panel using multi-criteria decision analysis to rank 20 drugs by 16 harm criteria spanning physical, psychological, and social dimensions. Their findings directly contradicted Schedule I assumptions:

- **Alcohol** ranked as the most harmful drug overall (score: 72/100), driven by harms to others
- **Heroin** (55) and **crack cocaine** (54) ranked second and third
- **Tobacco** (26) ranked sixth
- **Cannabis** (20) ranked eighth
- **Ketamine** (15) ranked eleventh
- **LSD** (7) and **psilocybin mushrooms** (6) ranked near the bottom — eighteenth and twentieth respectively, the least harmful of all 20 substances assessed

The placement of psilocybin and LSD alongside heroin in Schedule I, while alcohol and tobacco remain legally unrestricted, thus reflects political and cultural judgments rather than pharmacological evidence. David Nutt, then chair of the UK Advisory Council on the Misuse of Drugs, was dismissed from his government advisory position shortly after publishing these findings — an action widely interpreted as confirming the political rather than scientific basis of drug classification (Nutt, 2009).

#### 1.3.4 Economic Disincentives and the Pharmaceutical Industry

The research moratorium cannot be attributed solely to government prohibition. Structural features of the pharmaceutical industry create additional disincentives for psychedelic research. The conventional pharmaceutical business model relies on patent-protected compounds administered daily over months or years, generating recurring revenue. Psychedelic-assisted therapy, by contrast, involves substances that are either naturally occurring (psilocybin, DMT, mescaline) or off-patent (LSD, MDMA), administered in only one to three sessions, and requiring a combined drug-therapy intervention that does not fit neatly into existing FDA regulatory categories.

As Marks & Cohen (2021) noted, the potential for psychedelic therapy to displace chronic medication regimens represents a disruptive threat to the estimated $26 billion global antidepressant market. The absence of major pharmaceutical company investment in psychedelic research throughout the prohibition era — and the reliance on nonprofit organizations (MAPS, Usona Institute) and venture-backed startups (COMPASS Pathways, MindMed) for the current research revival — underscores the misalignment between conventional pharmaceutical incentives and single-dose therapeutic paradigms.

#### 1.3.5 The War on Consciousness

Beyond the explicitly political and economic dimensions, several scholars and public intellectuals have argued that the prohibition of psychedelics reflects a deeper cultural hostility toward non-ordinary states of consciousness. Graham Hancock, in his 2013 TED lecture and subsequent work *The Divine Spark* (2015), framed the criminalization of psychedelics as a "war on consciousness" — an argument that sovereign individuals should possess the right to explore their own consciousness using any means that does not harm others, and that the state's prohibition of such exploration represents a fundamental infringement on cognitive liberty.

This framing has been taken up in academic discourse by Boire (2000), who argued for "cognitive liberty" as a human right, and by Carhart-Harris & Nutt (2014), who described the prohibition of psychedelic research as "one of the most censorious interferences in scientific freedom in the modern era," noting that the Schedule I barriers — requiring expensive security infrastructure, DEA licensing, and months-long approval processes — have deterred all but the most determined researchers from entering the field.

#### 1.3.6 Implications for the Current Evidence Base

These historical, political, and economic forces have direct consequences for the methodological limitations noted in this review. The current psychedelic research renaissance is effectively rebuilding a clinical evidence base from a politically imposed ground zero, operating under Schedule I constraints that increase research costs by an estimated 5–10 fold relative to unscheduled compounds, limit the pool of participating institutions, and restrict participant access. That the evidence has nonetheless progressed to Phase 3 trials within approximately 15 years of the first modern RCTs — producing effect sizes that consistently exceed those of FDA-approved first-line treatments — speaks to the robustness of the therapeutic signal rather than its weakness.

The methodological limitations catalogued in this review (functional unblinding, small sample sizes, limited diversity, high risk of bias) are thus partly iatrogenic artifacts of a prohibition regime that was never grounded in clinical evidence. Acknowledging this context does not excuse methodological shortcomings, but it does reframe them: the question is not why the evidence for psychedelic therapy remains preliminary, but why — given the political, economic, and regulatory forces arrayed against this research — it has advanced as far as it has.

### 1.4 Scope and Aims

This expanded review synthesizes the meta-analytic and clinical trial evidence for psychedelic-assisted therapy across seven primary domains:

1. **Depression** (MDD and TRD) — psilocybin, LSD, DMT, and ayahuasca vs. placebo and vs. SSRIs
2. **PTSD** — MDMA-assisted therapy vs. placebo and vs. conventional treatments
3. **Substance use disorders** — psilocybin for alcohol and tobacco use disorder; ibogaine for opioid dependence
4. **Cancer-related existential distress** — psilocybin for depression and anxiety in life-threatening illness
5. **Obsessive-compulsive disorder** — psilocybin emerging evidence
6. **Eating disorders and cluster headache** — preliminary evidence
7. **Ketamine/esketamine** — as a comparator and fellow rapid-acting intervention

We additionally examine the neurobiological mechanisms of action, safety and adverse event data, cost-effectiveness, international regulatory developments, equity and access considerations, and ethical challenges in therapy delivery.

---

## 2. Neurobiological Mechanisms of Action

### 2.1 5-HT2A Receptor Agonism

Psilocybin is a prodrug of psilocin (4-OH-DMT), a non-selective serotonin receptor agonist with primary affinity for the 5-HT2A receptor. There is broad consensus that the subjective, behavioral, and neural effects of classic psychedelics are initiated via stimulation of cortical 5-HT2A receptors (Vollenweider & Preller, 2020). Human studies using the 5-HT2A/2C antagonist ketanserin demonstrate complete blockade of the psychedelic experience, confirming the necessary role of this receptor subtype (Preller et al., 2017).

PET neuroimaging with [11C]MDL 100,907 in humans has quantified cortical 5-HT2A receptor occupancy following a standard psilocybin dose at approximately 39.5% (±10.9% SD) across all cortical regions, with preferential occupancy (63–75%) in regions of the default mode network, including the subgenual anterior cingulate cortex and bilateral angular gyri (Barrett et al., 2022).

Downstream, 5-HT2A activation on layer V pyramidal neurons increases glutamatergic transmission in the prefrontal cortex while simultaneously enhancing GABAergic interneuron activity, producing a net desynchronization of cortical activity. This aligns with the "entropic brain hypothesis" proposed by Carhart-Harris et al. (2014), which posits that psychedelics increase the entropy (informational complexity) of spontaneous brain activity, temporarily dissolving the rigid, over-determined patterns of neural activity associated with pathological rumination.

However, the necessity of 5-HT2A activation for therapeutic — as opposed to subjective — effects has been challenged. Hesselgrave et al. (2021) demonstrated in mice that a single psilocybin injection reversed anhedonic responses and increased AMPA/NMDA ratios at hippocampal synapses, and critically, neither the behavioral nor electrophysiological effects were blocked by ketanserin. This raises the possibility that therapeutic neuroplasticity may be dissociable from the hallucinogenic experience.

### 2.2 Default Mode Network Modulation

The default mode network — comprising the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), precuneus, and angular gyri — shows disproportionately high metabolic activity under resting conditions and is implicated in self-referential processing, autobiographical memory, and mental time travel. Hyperconnectivity and hyperactivity within the DMN have been consistently linked to depressive rumination and the "stuck" quality of depressive cognition (Hamilton et al., 2015).

Seminal fMRI work by Carhart-Harris et al. (2012) demonstrated that psilocybin significantly decreased blood flow and BOLD signal in key DMN hubs, particularly the mPFC and PCC. Subsequent analysis revealed that mean functional connectivity within the DMN was significantly decreased under psilocybin compared to placebo, while between-network connectivity increased, suggesting a temporary dissolution of the normally segregated modular architecture of the brain.

A systematic review of 18 neuroimaging studies (Gattuso et al., 2023) confirmed that DMN modulation by psychedelics is one of the most replicated findings in the field, though the specific pattern (acute desynchronization followed by post-acute normalization of connectivity) may vary across compounds and time points.

Critically, Daws et al. (2022) demonstrated using fMRI in two clinical trials that psilocybin produced decreased brain network modularity (increased global integration/flexibility) specifically in 5-HT2A receptor-rich higher-order networks. This effect was not observed with escitalopram, suggesting that psilocybin's antidepressant mechanism is neurobiologically distinct from SSRIs: it increases inter-network functional connectivity rather than modulating serotonin reuptake. The magnitude of modularity decrease correlated with clinical improvement.

### 2.3 Neuroplasticity and Psychoplastogens

Classic psychedelics promote structural and functional neuroplasticity. The foundational in vitro and animal work by Ly et al. (2018) demonstrated that psilocybin, LSD, DMT, and DOI increase dendritic arbor complexity, spine density, and synaptogenesis in cortical neurons — effects mediated through 5-HT2A-dependent activation of TrkB, mTOR, and BDNF signaling pathways. Most psychedelics tested showed greater potency than ketamine, with LSD exhibiting an EC50 of 0.409 nM.

Olson (2018) coined the term "psychoplastogens" for this class of compounds that rapidly promote lasting neuroplasticity after a single dose, encompassing serotonergic psychedelics, ketamine (NMDA antagonist), and scopolamine (muscarinic antagonist). In a subsequent review, Olson (2022) detailed the intracellular signaling cascades and discussed tabernanthalog (TBG), a non-hallucinogenic psychoplastogen that repairs stress-damaged neural circuitry in animal models — raising the key unanswered question of whether the subjective psychedelic experience is necessary for neuroplastic effects.

Shao et al. (2021) provided compelling in vivo evidence using chronic two-photon microscopy of layer 5 pyramidal neurons in mouse medial frontal cortex, demonstrating that a single dose of psilocybin produced ~10% increases in spine size and density within 24 hours, with increased spine formation persisting for at least one month. Psilocybin also reversed stress-related behavioral deficits and increased excitatory neurotransmission, confirming that psilocybin-evoked synaptic rewiring is both rapid and enduring.

De Vos et al. (2021) conducted a systematic review of neuroplasticity mechanisms across psychedelics (ayahuasca, DMT, psilocybin, LSD), confirming that single administration changes expression of plasticity-related genes and proteins (including BDNF), that increased dendritic complexity outlasts acute psychedelic effects, and that repeated administration stimulated neurogenesis and increased BDNF mRNA levels up to one month post-treatment.

These neuroplastic changes may provide a biological substrate for the sustained therapeutic effects observed weeks to months after a single dosing session, potentially "resetting" aberrant neural circuitry underlying depression and PTSD.

### 2.4 MDMA: Distinct Mechanism

MDMA operates through a fundamentally different mechanism. Rather than direct 5-HT2A agonism, MDMA acts primarily as a serotonin-norepinephrine-dopamine releasing agent, binding to monoamine transporters (SERT, NET, DAT) and reversing their function, causing massive efflux of stored monoamines into the synaptic cleft. MDMA additionally stimulates oxytocin release, which is hypothesized to underlie its prosocial effects and its capacity to facilitate the therapeutic alliance. For PTSD specifically, MDMA's combination of anxiolysis, increased emotional empathy, and enhanced fear extinction learning is proposed to create a "window of tolerance" within which patients can engage with traumatic memories without overwhelming hyperarousal or dissociation (Mithoefer et al., 2016). Reconsolidation theory posits that MDMA may render fear memories labile during recall, enabling their modification with reduced emotional valence during integration.

---

## 3. Psilocybin for Depression: Meta-Analytic Evidence

### 3.1 Efficacy vs. Placebo

Multiple systematic reviews and meta-analyses published between 2023 and 2025 have quantified the antidepressant efficacy of psilocybin-assisted therapy:

| Meta-Analysis | k (studies) | N (participants) | Effect Size | Notes |
|---|---|---|---|---|
| Fang et al. (2024), *Frontiers in Psychiatry* | 8 RCTs | 524 | g = **-0.89** (I² = 70%) | Primary and secondary depression |
| Yao et al. (2024), *Psychiatry Research* | 126 articles (all psychedelics) | — | g = **-1.49** (psilocybin) | Psilocybin strongest of 4 psychedelics |
| Ko et al. (2023), *J Affective Disorders* | 5 RCTs | — | MD = **-9.55** (Day 15 MADRS) | 25 mg dose SUCRA = 92.25% |
| Metaxa & Clarke (2024), *BMJ* | 7 RCTs | 436 | g = **0.66** (I² = 0%) | Response RR = 2.17; Remission RR = 2.96 |
| Menon et al. (2025), *Acta Psychiatrica Scandinavica* | 6 RCTs | 427 | SMD = **-0.72** (I² = 17%) | Response RR = 3.42; Remission RR = 3.66 |
| Borgogna et al. (2025), *Psychopharmacology* | 9 RCTs | 602 | Significant incremental effect | High risk-of-bias noted |

**Interpretation:** Across meta-analyses, psilocybin-assisted therapy consistently demonstrates medium-to-large effect sizes for the reduction of depressive symptoms relative to placebo (g = -0.66 to -1.49). Notably, the more conservative estimates from Metaxa & Clarke (2024) and Menon et al. (2025) — which showed minimal heterogeneity (I² = 0–17%) — converge around g = 0.66–0.72, while studies with higher heterogeneity yield larger estimates. For context, SSRIs typically achieve effect sizes of g ≈ 0.30 vs. placebo in meta-analyses (Cipriani et al., 2018; Leucht et al., 2012), meaning psilocybin's effect magnitude is approximately 2–4 times larger even by conservative estimates.

### 3.2 Pivotal Randomized Controlled Trials

**Davis et al. (2021)** — Johns Hopkins, N=27, randomized waitlist-controlled: Two psilocybin sessions (20 + 30 mg/70 kg) with supportive psychotherapy produced a between-group Cohen's d = **2.5** on GRID-HAMD at week 1 (p < .001), with 71% response and 54% remission at week 4.

**Goodwin et al. (2022)** — COMPASS COMP360 Phase 2b, N=233, multi-site, double-blind, dose-finding: COMP360 25 mg vs. 10 mg vs. 1 mg (control) for TRD. The 25 mg dose showed LS mean MADRS difference = **-6.6** vs. 1 mg (p < .001), with 29% remission at week 3. The 10 mg dose did not separate from control, establishing a clear dose-response.

**Raison et al. (2023)** — USONA Phase 2, N=104, double-blind, placebo-controlled: Single 25 mg psilocybin vs. 100 mg niacin (active placebo) for MDD. MADRS mean difference = **-12.3** at day 43 (p < .001) and **-12.0** at day 8 (p < .001). Significant improvement in functional disability (SDS: difference = -2.31, p < .001). No serious treatment-emergent adverse events.

**Von Rotz et al. (2023)** — Double-blind RCT, N=52, MDD: Single 0.215 mg/kg psilocybin vs. placebo. Cohen's d = **0.97** on MADRS at day 14 (p = 0.001). Remission rate 54%.

**Rosenblat et al. (2024)** — Randomized waitlist-controlled, N=30, TRD (including MDD and bipolar II with comorbidities): 25 mg psilocybin, 1–3 sessions. Hedge's g = **1.07** at week 2. First RCT to include bipolar II and permit repeat dosing.

### 3.3 Phase 3 Trials

**COMP005** (COMPASS Pathways, 2025) — Phase 3, double-blind, placebo-controlled, N=258, TRD: Single COMP360 25 mg. Mean MADRS treatment difference = **-3.6** (95% CI -5.7 to -1.5; p < .001). 25% achieved ≥25% MADRS reduction at week 6 and maintained through week 26.

**COMP006** (COMPASS Pathways, February 2026) — Phase 3, double-blind, N=TRD: Two fixed doses of COMP360 25 mg (3 weeks apart) vs. 1 mg control. Mean treatment difference = **-3.8** (p < .001). 39% response rate. Effects observed as early as 1 day post-administration.

The Phase 3 MADRS deltas (-3.6 to -3.8 points) are notably more modest than earlier Phase 2 estimates, illustrating the typical attenuation of effect sizes as trials become larger and better controlled — a pattern consistent across psychiatric drug development.

### 3.4 Psilocybin vs. Escitalopram (Head-to-Head)

The most informative direct comparison comes from Carhart-Harris et al. (2021), a phase 2 double-blind RCT (N=59) comparing psilocybin (two 25 mg sessions) against a 6-week course of escitalopram (a first-line SSRI) for moderate-to-severe MDD. On the primary outcome (QIDS-SR-16), the between-group difference was not statistically significant (p = 0.17). However, psilocybin was significantly superior on all secondary outcomes, including MADRS, BDI-1a, and HAMD-17, and produced a significantly higher remission rate (57% vs. 28%).

Erritzoe et al. (2024) reported the 6-month observational follow-up of this trial. Depression scores remained comparable between groups at 6 months (QIDS-SR-16 difference = 1.51, p = 0.311), but psilocybin showed significant superiority on work/social adjustment (WSAS: difference -7.46, p < .001), meaning in life (MLQ: difference 4.86, p = 0.021), and connectedness (WCS: difference 11.02, p = 0.033). These findings suggest that psilocybin's benefits extend beyond symptom reduction to broader psychological well-being.

### 3.5 Dose-Response Relationship

The network meta-analysis by Ko et al. (2023) identified 25 mg as the optimal dose (SUCRA value = 92.25%), with statistically significant reductions in depressive symptoms emerging at Day 8 (MD = -7.42 vs. placebo) and Day 15 (MD = -9.55) but not at Day 2, indicating a time-dependent therapeutic trajectory. This rapid onset nonetheless substantially outpaces the 4–8 week latency of SSRIs. Swieczkowski et al. (2025) confirmed this dose-response in a network meta-analysis of 3 RCTs (N=389), finding 25 mg consistently superior to lower doses across timepoints.

### 3.6 Long-Term Follow-Up

**Gukasyan et al. (2022)** — 12-month follow-up of the Davis et al. (2021) trial: GRID-HAMD scores remained low (7.7 at 12 months vs. 22.8 at baseline), with 75% response and 58% remission at 12 months. Antidepressant effects of psilocybin-assisted therapy appear sustained for at least one year.

**Goodwin et al. (2025)** — 52-week observational follow-up of COMP360: Median time to depressive event was **189 days** for the 25 mg group vs. 43 days (10 mg) and 21 days (1 mg), demonstrating substantially longer maintenance of antidepressant effect at the therapeutic dose.

### 3.7 Therapy Hours

A meta-analysis by Hultgren et al. (2025) in *General Hospital Psychiatry* examined whether the number of therapy hours provided alongside psilocybin administration was associated with treatment outcomes. No significant association was found between therapy hours and symptom reduction. However, the authors cautioned that small sample sizes, heterogeneity, and poor reporting of the therapeutic component limit firm conclusions.

### 3.8 Number Needed to Treat

Wong et al. (2024) compared psilocybin and esketamine using NNT analysis in TRD: psilocybin 25 mg achieved an NNT = **5** at 21 days, compared to esketamine 56 mg NNT = 7 and esketamine 84 mg NNT = 7, suggesting a modest advantage for psilocybin's benefit-to-harm ratio.

---

## 4. Beyond Psilocybin: Other Psychedelics for Depression and Anxiety

### 4.1 LSD-Assisted Therapy

**Holze et al. (2023)** conducted a Phase II double-blind, placebo-controlled crossover trial (N=42) of LSD 200 μg for anxiety with and without life-threatening illness. At 16 weeks, LSD produced robust effect sizes: STAI-G reduction d = **-1.18** (p = 0.007); HAM-D-21 reduction d = **-1.1** (p = 0.0004); clinical response (≥30% STAI-G reduction) 65% LSD vs. 9% placebo. A 12-month follow-up (Holze et al., 2024) confirmed sustained reductions in anxiety, depression, and general psychiatric symptomatology with minimal lasting negative effects.

**Muller et al. (2025)** reported a randomized, double-blind trial (N=61) of low-dose (25 μg × 2) vs. high-dose (100 + 200 μg) LSD for major depression. IDS-SR change favored the high-dose group by 7.9 points.

**MindMed MM120** (Goodwin et al., 2025, *JAMA*) — Phase 2b, multicenter, double-blind, placebo-controlled trial (N=198) of lysergide d-tartrate for generalized anxiety disorder. The 100 μg dose showed 65% response and 48% remission at week 12, leading to FDA Breakthrough Therapy Designation (March 2024). Phase 3 trials are underway.

### 4.2 DMT and 5-MeO-DMT

**SPL026 (N,N-DMT)** — Erritzoe et al. (2026) published Phase 2a results in *Nature Medicine*: N=34 with moderate/severe MDD, single 21.5 mg IV DMT. MADRS reduction -7.35 vs. placebo at 2 weeks (p = 0.023); at 1 week, difference -10.8 (p = 0.002). 57% remission at 12 weeks following a single 20-30 minute psychedelic experience.

**GH001 (5-MeO-DMT)** — Reckweg et al. (2023) reported Phase 1/2 results for inhaled 5-MeO-DMT in TRD: using an individualized dosing regimen (6, 12, 18 mg escalating in a single day), 87.5% (7/8) achieved remission at Day 7. Phase 2b results (2024, press release): MADRS reduction -15.2 (GH001) vs. +0.3 (placebo) at Day 8 (difference -15.5, p < 0.0001); 57.5% remission vs. 0% placebo. Open-label extension showed 77.8% remission at 6 months, with 63% needing only 1–4 treatments. Notably, 97.4% were discharge-ready within 1 hour.

### 4.3 Ayahuasca for Depression

**Palhano-Fontes et al. (2019)** conducted the first parallel-arm, double-blind RCT (N=29) of ayahuasca for TRD. MADRS scores were significantly lower in the ayahuasca group at Day 1, Day 2, and Day 7 (p < 0.0001). Effect sizes increased over time: Day 1 Cohen's d = 0.84; Day 2 d = 0.84; Day 7 d = **1.49**. Response rates at Day 7: 64% ayahuasca vs. 27% placebo.

**Sanches et al. (2016)** — Open-label study (N=17) of single-dose ayahuasca for recurrent depression, with SPECT neuroimaging showing increased perfusion in left nucleus accumbens, right insula, and left subgenual area. Significant HAM-D and MADRS decreases persisted through Day 21.

### 4.4 Ketamine and Esketamine as Comparators

Ketamine represents the most clinically advanced rapid-acting antidepressant comparator. Intranasal esketamine (Spravato) received FDA approval for TRD in March 2019, for MDD with suicidal ideation in August 2020, and as the first monotherapy for TRD in January 2025.

Alnefeesi et al. (2022) conducted a real-world meta-analysis of ketamine in TRD (79 studies, N=2,665): response rate 45%, remission rate 30%, Hedges' g = **1.44** for symptom improvement. The anti-suicidal effect of ketamine is particularly notable: Wilkinson et al. (2018) demonstrated rapid reduction in suicidal ideation within 1 day (d = 0.48–0.85), partially independent of the antidepressant effect.

McIntyre et al. (2021) synthesized international expert opinion confirming ketamine/esketamine's rapid-acting antidepressant properties with acceptable safety, though requiring repeated administration (typically weekly to biweekly) to maintain effects — in contrast to psilocybin's potential for sustained benefit after 1–2 sessions.

---

## 5. Cancer-Related Existential Distress

Two landmark trials in 2016 demonstrated that psilocybin produces substantial and sustained reductions in depression and anxiety in patients with life-threatening cancer diagnoses.

**Griffiths et al. (2016)** — Johns Hopkins, double-blind crossover RCT, N=51: High-dose (22–30 mg/70 kg) vs. low-dose (1–3 mg/70 kg) psilocybin. Effect sizes for high- vs. low-dose at post-session 1: GRID-HAMD depression d = **1.30**, HAM-A anxiety d = **1.23**. Combined baseline-to-6-month effect sizes were exceptionally large: HAM-A d = **3.40**, GRID-HAMD d = **2.98**. At 6 months, 78% showed clinically significant decreases in depression; 83% in anxiety. Approximately 80% attributed the experience personal meaning rated "among the most meaningful" of their lives.

**Ross et al. (2016)** — NYU, double-blind, placebo-controlled crossover, N=29: 0.3 mg/kg psilocybin vs. niacin 250 mg. Antidepressant response (BDI) at 7 weeks: 83% psilocybin vs. 14% placebo. Anxiolytic response (HADS-A): 58% vs. 14%. Mystical experience mediated therapeutic effects on 4 of 6 primary measures.

**Agin-Liebes et al. (2020)** — 4.5-year follow-up of the Ross et al. trial: sustained reductions in anxiety, depression, hopelessness, demoralization, and death anxiety with large within-group effect sizes. Approximately 60–80% met criteria for clinically significant antidepressant/anxiolytic responses at 4.5 years. 71–100% attributed positive life changes to the psilocybin experience.

These findings are particularly significant because cancer-related distress is among the most treatment-resistant forms of depression and anxiety, and the durability of response (4.5+ years after a single session) far exceeds any known pharmacological intervention.

---

## 6. MDMA-Assisted Therapy for PTSD: Meta-Analytic Evidence

### 6.1 Phase 3 Pivotal Trials

Two randomized, double-blind, placebo-controlled phase 3 trials (MAPP1 and MAPP2) provide the strongest evidence for MDMA-assisted therapy (MDMA-AT) in PTSD:

**MAPP1** (Mitchell et al., 2021; N=90):
- Population: Severe PTSD, including comorbid dissociation, depression, and history of SUD
- MDMA group CAPS-5 change: **-24.4** vs. placebo **-13.9**
- Effect size: Cohen's d = **0.91** (p < 0.0001)
- 67% of MDMA group no longer met PTSD diagnostic criteria vs. 32% placebo

**MAPP2** (Mitchell et al., 2023; N=104):
- Population: Moderate-to-severe PTSD; ethnoracially diverse sample (26.9% Hispanic/Latino, 33.7% non-White)
- MDMA group CAPS-5 change: **-23.7** vs. placebo **-14.8**
- Effect size: Cohen's d = **0.7** (p < 0.001)
- 71.2% of MDMA group no longer met PTSD diagnostic criteria vs. 47.6% placebo
- Secondary outcome (SDS functional impairment): d = **0.4** (p = 0.03)

### 6.2 Dose-Response and Phase 2 Evidence

Ot'alora G et al. (2018) conducted a blinded Phase 2 dose-response trial (N=28) comparing MDMA 40 mg (control), 100 mg, and 125 mg for chronic PTSD. Mean CAPS-IV change at 1 month after 2 sessions: -26.3 (125 mg), -24.4 (100 mg), -11.5 (40 mg). Statistical significance was reached in the per-protocol set (p = 0.03) but not ITT, likely due to the small sample.

### 6.3 Meta-Analytic Synthesis

Multiple systematic reviews confirm the efficacy signal:

- **Yang, J., et al. (2024)** — 7 RCTs, phases 2 and 3, demonstrating consistent CAPS score reductions vs. placebo/active controls.
- **Shahrour et al. (2024)** — 9 studies, N=297, confirming efficacy across trials.
- **Yong et al. (2025)** — Overview of all published systematic reviews and meta-analyses, searched 6 databases through May 2024, confirming consistent efficacy signals across methodologies.

### 6.4 Long-Term Follow-Up

**Mithoefer et al. (2013)** — Long-term follow-up (mean 45.4 months) of the original Phase 2 trial: N=16 completers. CAPS scores at long-term follow-up were not statistically different from 2-month post-treatment scores, indicating durable effects. Only 2/16 (13%) showed relapse to moderate-severe PTSD.

The MPLONG study provided observational follow-up of MAPP1/MAPP2 participants at 6–24+ months. CAPS-5 improvements in MDMA-treated patients persisted beyond 6 months, though data were fragmented across time windows.

**Note on Jerome et al. (2020):** A pooled analysis of six Phase 2 trials that reported sustained CAPS-IV improvements at long-term follow-up was **retracted** in 2024 (*Psychopharmacology* 241, 2407) following disclosure of unethical conduct at one trial site (MP4). This retraction underscores the importance of rigorous oversight in psychedelic clinical research.

### 6.5 Comparison with Conventional PTSD Treatments

Stanicic et al. (2025) conducted a systematic literature review comparing MDMA-AT against current treatment options for chronic, treatment-resistant PTSD:

- **MDMA-AT** showed consistent improvements in CAPS scores and rates of diagnostic remission (67–71%)
- **FDA-approved medications** (sertraline, paroxetine): typical effect sizes d ≈ 0.3–0.4, remission rates 20–30%
- **Trauma-focused psychotherapy** (PE, CPT, EMDR): d ≈ 0.8–1.0 (Bradley et al., 2005; Powers et al., 2010), but dropout rates 18–36%

Powers et al. (2010) meta-analyzed prolonged exposure (PE) for PTSD across 13 studies (N=675), finding Hedges' g = **1.08** vs. control. PE-treated patients fared better than 86% of control patients, but no significant difference was found between PE and other active treatments (CPT, EMDR). Bradley et al. (2005) reported a pre-post effect size of d = **1.43** across all trauma-focused therapies.

The effect sizes for MDMA-AT (d = 0.7–0.91) thus exceed those of FDA-approved PTSD pharmacotherapy by 2–3 fold and are comparable to those of trauma-focused psychotherapy, with the advantage of requiring only 3 dosing sessions rather than 12–16 weekly therapy sessions.

### 6.6 FDA Rejection and Regulatory Status

Despite the robust clinical data, the FDA Psychopharmacologic Drug Advisory Committee voted 9–2 against effectiveness and 10–1 that benefits did not outweigh risks on June 4, 2024. The FDA issued a Complete Response Letter on August 9, 2024, citing:

1. **Functional unblinding:** Over 90% of MAPP1 participants correctly guessed their assignment
2. **Safety reporting concerns:** Inconsistencies in adverse event documentation; allegations of misconduct at the MP4 trial site
3. **Inability to parse drug vs. therapy effects:** The FDA does not regulate psychotherapy, making evaluation of the combined intervention challenging
4. **Durability:** Insufficient long-term follow-up data
5. **Trial design:** The FDA requested a third phase 3 trial

### 6.7 Ibogaine for Trauma and Opioid Dependence

**Williams et al. (2024)** published a prospective observational study in *Nature Medicine* of magnesium-ibogaine therapy in N=30 male Special Operations Forces veterans with traumatic brain injuries. Results were striking: WHODAS disability scores improved from 30.2 to 5.1 at 1 month. At 1 month: 100% PTSD response, 97% depression response, 93% anxiety response; 86% PTSD remission, 83% depression remission. No cardiac arrhythmias or serious treatment-emergent adverse events.

**Noller et al. (2018)** — Prospective observational study (N=14) of ibogaine for opioid dependence in New Zealand, with 12-month follow-up: significant reductions in ASI-Lite drug use composite scores and BDI-II depression scores. A single ibogaine treatment reduced opioid withdrawal and achieved sustained cessation or reduced use.

Ibogaine's cardiovascular risk profile (QT prolongation) necessitates medical monitoring, distinguishing it from classic psychedelics. The State of Texas awarded $50 million in December 2025 to UTMB Health and UTHealth Houston to lead multicenter ibogaine clinical trials for addiction, TBI, and behavioral health.

---

## 7. Psychedelics for Substance Use Disorders

### 7.1 Alcohol Use Disorder

**Bogenschutz et al. (2022)** — Double-blind, placebo-controlled RCT (N=93) of psilocybin-assisted therapy for AUD. Percentage of heavy drinking days during the 32-week double-blind period was significantly lower for psilocybin vs. diphenhydramine (active placebo): mean difference = 13.9 percentage points (p = 0.01). Between-group Cohen's d = **0.62**.

For comparison, Jonas et al. (2014) meta-analyzed pharmacotherapy for AUD across 122 RCTs (N=22,803): acamprosate NNT = **12** to prevent return to any drinking; oral naltrexone 50 mg NNT = **20** to prevent return to any drinking, NNT = **12** to prevent heavy drinking. The relative efficacy of psilocybin appears comparable or superior to existing pharmacotherapies, though direct comparison is limited by differing outcome measures.

**Rieser et al. (2025)** — An important null result: a separate Phase 2 RCT of psilocybin for AUD relapse prevention (post-withdrawal, single dose) found **no** significant impact on abstinence or alcohol use levels, suggesting that the intervention context (active drinking vs. post-withdrawal) matters substantially.

Historical evidence from Krebs & Johansen (2012), a meta-analysis of 6 RCTs (N=536) evaluating LSD for alcoholism, found beneficial effects comparable to disulfiram.

### 7.2 Tobacco Use Disorder

**Johnson et al. (2014)** — Open-label pilot (N=15) of psilocybin-assisted therapy (20 + 30 mg/70 kg) with manualized CBT-based smoking cessation protocol: 80% biologically verified abstinence at 6 months. **Johnson et al. (2017)** reported long-term follow-up: 67% abstinent at 12 months, 60% at mean 30 months post-quit date. Garcia-Romeu et al. (2014) demonstrated that mystical experience scores significantly correlated with cessation outcomes.

For comparison, Cahill et al. (2013) meta-analyzed pharmacological smoking cessation interventions across 267 studies (N=101,804): varenicline vs. placebo OR = **2.88** (~35% quit rates); NRT vs. placebo OR = **1.84** (~25% quit rates); bupropion vs. placebo OR = **1.82** (~25% quit rates). Psilocybin's 60–80% abstinence rates in open-label studies substantially exceed all conventional pharmacotherapies, though randomized confirmation is needed.

A randomized controlled trial comparing psilocybin (30 mg/70 kg) vs. nicotine patch is underway, with interim data (N=44) showing 12-month point-prevalence abstinence of 59% (psilocybin) vs. 27% (patch).

### 7.3 Ayahuasca for Addiction

Thomas et al. (2013) conducted an observational study of ayahuasca-assisted therapy in a rural First Nations community in Canada (N=12), combining group counseling with ayahuasca ceremonies. Self-reported cocaine use significantly declined at 6 months, and all participants reported positive and lasting changes.

### 7.4 Meta-Analytic Overview

Van der Meer et al. (2023) systematically reviewed 4 clinical trials (N=151) of psilocybin for SUDs (3 AUD, 1 TUD), finding beneficial effects in all. Keighley et al. (2025) conducted a broader systematic review and meta-analysis of 30 studies evaluating LSD, psilocybin, ketamine, and ibogaine for SUDs, demonstrating positive results for abstinence, reduced substance use, craving, and withdrawal across compounds, though insufficient data to establish superiority of any specific psychedelic.

---

## 8. Emerging Indications

### 8.1 Obsessive-Compulsive Disorder

Beyond the foundational Moreno et al. (2006) open-label study (N=9, 23–100% Y-BOCS reduction), recent trials have advanced the evidence:

**Pellegrini et al. (2025)** — Pharmacological challenge study in which participants received 1 mg then 10 mg psilocybin (fixed order, 4 weeks apart). The 10 mg dose produced rapid-onset, moderate-to-large effects on **compulsions** (not obsessions or depression) lasting up to 1 week.

**Goodman et al. (Yale, NCT03356483)** — Completed November 2024. Randomized, double-blind, niacin placebo-controlled trial of single moderate dose (0.25 mg/kg) psilocybin for treatment-refractory OCD. Results indicated clinically significant mean reductions in OCD symptoms in psilocybin vs. placebo at 48-hour primary endpoint. Full peer-reviewed publication pending.

**Ching et al. (2024)** — Protocol published for a randomized, waitlist-controlled trial of repeated psilocybin dosing combined with non-directive support for OCD (N=30 target).

### 8.2 Eating Disorders

**Knatz Peck et al. (2023)** — First clinical trial of psilocybin for anorexia nervosa, published in *Nature Medicine*. Open-label Phase 1 feasibility study (N=10 adult females): Single 25 mg COMP360 psilocybin showed no clinically significant safety concerns. At least 6 active clinical trials across North America, Australia, and Europe are investigating psilocybin for anorexia, binge eating disorder, and body dysmorphic disorder.

### 8.3 Cluster Headache

**Sewell et al. (2006)** — Foundational case series (N=53 cluster headache patients): 85% reported psilocybin aborted acute attacks; 52% reported cluster period termination; 95% reported remission extension.

**Schindler et al. (2022)** — First RCT (N=16): 3 low-dose psilocybin sessions (0.143 mg/kg, 5 days apart). Primary outcome non-significant, but responders showed ~75% attack frequency reduction. **Schindler et al. (2024)** reported the blinded extension: attack frequency significantly reduced from 18.4 to 9.8 attacks/week (~50% reduction, p = 0.013, d' = **0.97**). Additional trials for migraine prevention are underway (Schindler et al., 2025).

---

## 9. Safety and Adverse Events

### 9.1 General Safety Profile

Classic serotonergic psychedelics have a remarkably favorable safety profile in controlled settings. Psilocybin has an LD50 of 280 mg/kg in rats — over 700 times the clinical dose of 25 mg for a 70 kg human. Classic psychedelics are not addictive and show rapid tolerance (tachyphylaxis), making compulsive use patterns pharmacologically improbable.

### 9.2 Systematic Review of Adverse Events

Hinkle et al. (2024) published a systematic review and meta-analysis in *JAMA Psychiatry* examining adverse events across 114 studies involving 3,504 participants:

- **Serious adverse events (SAEs)** were rare; none occurred in healthy participants
- ~4% of individuals with pre-existing neuropsychiatric disorders experienced SAEs
- **No cases of suicide, persistent psychosis, or HPPD** reported in modern clinical research
- Common nonserious adverse events: headache, nausea, transient anxiety, fatigue

Schlag et al. (2022) concluded that many persistent negative perceptions of psychological risks from psychedelics are unsupported by available evidence in regulated/clinical contexts. Aday et al. (2020) synthesized 34 experimental studies with ≥2-week follow-up, finding limited aversive effects with proper screening, preparation, and support.

### 9.3 Challenging Experiences

Barrett et al. (2016) developed and validated the Challenging Experience Questionnaire (CEQ), a 26-item instrument measuring seven dimensions: fear, grief, physical distress, insanity, isolation, death, and paranoia. This has been adopted as a standardized measure across clinical trials. Challenging experiences are common (occurring in a substantial minority of sessions) but are typically transient and, paradoxically, may correlate with greater therapeutic benefit when processed with adequate support.

### 9.4 Comparison with SSRI Side Effects

| Domain | Psilocybin (acute, 1–2 sessions) | SSRIs (chronic, daily) |
|---|---|---|
| Sexual dysfunction | Not reported | 25–73% of patients |
| Weight gain | Not reported | Common (particularly paroxetine) |
| Emotional blunting | Not reported | 40–60% of patients |
| Discontinuation syndrome | Not applicable | Common; can be severe |
| Nausea | Common (acute, transient) | Common (first 1–2 weeks) |
| Headache | Common (acute, transient) | Common |
| Suicidality | Rare (monitored settings) | Black box warning (age < 25) |

The critical distinction is that psilocybin's adverse effects are acute and transient, whereas SSRI side effects are chronic and persist throughout the treatment course, which may span months to years.

### 9.5 Cardiovascular Safety

Classic psychedelics produce modest, transient increases in heart rate and blood pressure. Wsol (2023) reviewed cardiovascular effects across clinical trials: tachycardia (>100 bpm) in ~7% of psilocybin administrations; hypertension (systolic BP >140 mmHg) in ~50% — all transient and without requiring medical intervention. Rouaud et al. (2024) noted that both LSD and psilocybin bind 5-HT2B with potency comparable to known cardiotoxins, but no clinical reports of valvular heart disease from psychedelic use exist. The intermittent dosing schedule (1–3 sessions vs. chronic daily administration) markedly reduces this theoretical risk. The authors recommended echocardiographic monitoring for prolonged microdosing regimens.

Ibogaine represents an exception, with documented QT prolongation and cardiac arrhythmia risk requiring continuous cardiac monitoring during treatment.

### 9.6 Hallucinogen Persisting Perception Disorder (HPPD)

HPPD Type 2 (chronic, persistent) is widely cited as rare, though precise prevalence estimates remain elusive due to underreporting and methodological challenges. Orsolini et al. (2017) systematically reviewed the HPPD literature, noting that overall prevalence "has been generally considered low" without quantifying a specific rate. Halpern et al. (2018) identified risk factors including pre-existing psychological vulnerability, polydrug use, and repeated high-dose use, noting that prevalence estimates range widely (from ~4.2% for any visual disturbance to extremely rare chronic forms). No cases have been reported in modern clinical research involving thousands of screened participants, suggesting that risk in controlled, screened, supported settings is extremely low.

### 9.7 Serotonin Toxicity

Drug-drug interactions with serotonergic medications present a theoretical risk of serotonin syndrome, particularly with MDMA (massive serotonin efflux) and ayahuasca (MAO inhibitors). Clinical trials address this through mandatory washout periods. Reported cases are rare and typically involve polydrug use outside clinical settings.

### 9.8 Safety Guidelines

Johnson et al. (2008) published foundational safety guidelines for hallucinogen research, identifying the most likely risk as overwhelming psychological distress during drug action potentially leading to dangerous behavior. Recommended safeguards include: thorough screening (psychiatric/family history of psychosis), trained interpersonal support, controlled physical environment, preparation sessions, and follow-up integration. These guidelines have been adopted by all major research programs.

---

## 10. Critical Appraisal and Limitations

### 10.1 Risk of Bias

The incremental efficacy meta-analysis by Borgogna et al. (2025) found that most psilocybin RCTs demonstrated **high risk of bias**, particularly regarding:

- **Functional unblinding:** Psychoactive substances produce obvious subjective effects, making true double-blinding impossible. In MAPP1, over 90% of participants correctly guessed their treatment assignment.
- **Small sample sizes:** The largest psilocybin depression RCTs include fewer than 260 participants
- **Short follow-up:** Most studies report outcomes at 3–6 weeks; long-term durability data remain limited
- **Allegiance effects:** Many trials have been conducted by investigators with strong prior commitments to the psychedelic therapy paradigm

### 10.2 The Blinding Problem

This is arguably the most significant methodological challenge. When participants know they received the active treatment, psychological factors (hope, meaning-making, perceived specialness of the experience) may contribute substantially to symptom improvement. The FDA's advisory committee identified this as a central concern in their vote against MDMA approval.

Proposed solutions include active placebo controls (low-dose psychedelic or niacin to produce somatic effects), though these only partially address the problem. Alternative trial designs — dismantling studies, dose-response designs, delayed-start designs — may be more appropriate than traditional double-blind placebo-controlled paradigms.

### 10.3 Incremental vs. Net Effect Sizes

Borgogna et al. (2025) raised an important distinction: most meta-analyses report **net** therapeutic effects, but the clinically relevant quantity is the **incremental** effect (treatment minus control). Since placebo groups in psychedelic trials often show substantial improvement (due to intensive therapeutic contact, expectancy, and attention), the incremental benefit of the psychedelic itself may be smaller than headline effect sizes suggest.

This concern is partially validated by the Phase 3 COMP360 results: MADRS deltas of -3.6 to -3.8 points are notably smaller than the Phase 2 estimates, suggesting that as trial methodology improves, effect sizes moderate — a pattern entirely consistent with psychiatric drug development more broadly (Turner et al., 2008).

### 10.4 Generalizability

Clinical trial participants are highly selected: individuals with psychotic disorders, bipolar disorder (with rare exceptions — Rosenblat et al., 2024), active suicidality, and significant medical comorbidities are typically excluded. Michaels et al. (2018) reviewed 18 psychedelic studies (N=282) and found participants were 82.3% non-Hispanic White, 2.5% African-American, 2.1% Latino, raising serious questions about generalizability (see Section 13).

### 10.5 Adverse Event Reporting

Breeksema et al. (2022) found that many psychedelic trials did not systematically assess adverse events, and reporting was inconsistent. Standardized adverse event monitoring protocols are needed. The retraction of Jerome et al. (2020) following disclosure of ethical violations at a trial site further underscores the need for rigorous independent oversight.

---

## 11. Comparative Summary

### Table 1: Effect Sizes Across Treatment Modalities for Depression

| Intervention | Comparator | Effect Size | Onset | Sessions/Duration |
|---|---|---|---|---|
| Psilocybin 25 mg | Placebo | g = -0.66 to -1.49 | Days 8–15 | 1–2 sessions |
| Psilocybin 25 mg (Phase 3) | Placebo | ΔMADRS = -3.6 to -3.8 | Day 1 | 1–2 sessions |
| SSRIs (pooled) | Placebo | g ≈ -0.30 | 4–8 weeks | Daily, indefinite |
| SSRIs (FDA-corrected) | Placebo | ~32% smaller than published | 4–8 weeks | Daily, indefinite |
| Psilocybin 25 mg | Escitalopram | Favored on secondary outcomes | Days vs. weeks | 2 sessions vs. 6 weeks |
| CBT | Waitlist/TAU | g ≈ -0.65 to -0.75 | 8–16 weeks | 12–20 sessions |
| Ketamine (IV) | Placebo | g ≈ -1.44 (real-world) | Hours | Repeated infusions |
| Esketamine (nasal) | Placebo | ΔMADRS ≈ -4.0 | Hours–days | Repeated, twice-weekly |
| LSD 200 μg | Placebo | d = -1.1 (HAM-D) | Weeks | 2 sessions |
| Ayahuasca | Placebo | d = 0.84–1.49 | Day 1–7 | Single session |
| DMT (IV, SPL026) | Placebo | ΔMADRS = -7.35 | 1 week | Single 20-min session |
| 5-MeO-DMT (GH001) | Placebo | ΔMADRS = -15.5 | Day 8 | 1–4 sessions |
| Psilocybin NNT (TRD) | — | NNT = 5 at 21 days | — | — |
| Esketamine NNT (TRD) | — | NNT = 7 | — | — |

### Table 2: Effect Sizes Across Treatment Modalities for PTSD

| Intervention | Comparator | Effect Size | Remission Rate | Sessions |
|---|---|---|---|---|
| MDMA-AT | Placebo + therapy | d = 0.70–0.91 | 67–71% | 3 dosing sessions |
| Sertraline/Paroxetine | Placebo | d ≈ 0.30–0.40 | 20–30% | Daily, indefinite |
| Prolonged Exposure | Control | g = 1.08 | 40–60% | 12–16 sessions |
| All trauma-focused therapy | Wait-list | d = 1.43 (pre-post) | >50% completers | 12–16 sessions |
| Magnesium-Ibogaine | Pre-post observational | — | 86% PTSD remission | Single session |

### Table 3: Effect Sizes for Substance Use Disorders

| Intervention | Indication | Effect/Outcome | Comparator | Source |
|---|---|---|---|---|
| Psilocybin + therapy | AUD | d = 0.62 (heavy drinking days) | Diphenhydramine | Bogenschutz 2022 |
| Psilocybin + CBT | TUD | 80% abstinence at 6 mo | Open-label | Johnson 2014 |
| Psilocybin + CBT | TUD | 60% abstinence at 30 mo | Open-label | Johnson 2017 |
| Acamprosate | AUD | NNT = 12 (any drinking) | Placebo | Jonas 2014 |
| Naltrexone 50 mg | AUD | NNT = 12 (heavy drinking) | Placebo | Jonas 2014 |
| Varenicline | TUD | OR = 2.88 (~35% quit rate) | Placebo | Cahill 2013 |
| NRT | TUD | OR = 1.84 (~25% quit rate) | Placebo | Cahill 2013 |
| Ibogaine | Opioid dependence | Sustained reduced use at 12 mo | Pre-post observational | Noller 2018 |

---

## 12. Cost-Effectiveness and Health Economics

The economic implications of psychedelic-assisted therapy are potentially transformative. Unlike conventional pharmacotherapy requiring chronic daily administration, psychedelic therapy involves 1–3 dosing sessions — though with intensive therapeutic support.

**Marseille et al. (2020)** developed a decision-analytic Markov model for MDMA-AT for PTSD (30-year time horizon): for 1,000 patients, reduces general and mental health care costs by $103.2 million. Break-even within ~3.1 years. **Marseille et al. (2022)** updated the model using MAPP1 Phase 3 data: MDMA-AT cost per patient $11,537; for 1,000 patients, discounted net savings of $132.9 million, generating 4,856 QALYs and averting 61.4 premature deaths. ICER: $2,384/QALY (highly cost-effective by any threshold).

**McCrone et al. (2023)** modeled psilocybin-assisted therapy for severe depression in the UK: psilocybin generated more QALYs (0.310) than CBT alone (0.283), medication alone (0.278), or combination (0.287). Cost-effectiveness depends critically on therapist support costs and drug pricing.

**Avanceña et al. (2025)** modeled psilocybin for TRD in the US over 12 months: total PAT cost assumed at $5,000, producing 0.031 additional QALYs vs. standard of care. ICER: $117,517/QALY — potentially cost-effective at the $150,000/QALY threshold.

Marseille et al. (2022b) outlined the broader research agenda for psychedelic therapy economics, noting unique methodological challenges: extended therapist labor costs (6–8 hour accompanied sessions), therapist training requirements, and facility costs for dedicated treatment spaces.

---

## 13. Equity, Diversity, and Access

### 13.1 Representation in Clinical Trials

Michaels et al. (2018) reviewed 18 psychedelic studies (1993–2017, N=282 participants): **82.3%** non-Hispanic White, 2.5% African-American, 2.1% Latino, 1.8% Asian, 4.6% Indigenous, 4.6% mixed race. These demographics raise fundamental questions about the generalizability of treatment outcomes.

George et al. (2020) examined how the psychedelic medicine movement, while owing much to indigenous healing practices, has largely excluded indigenous and BIPOC communities from its benefits. Historical factors — particularly the disproportionate impact of the 1970 Controlled Substances Act on racial and ethnic minorities — continue to shape unequal access.

Thrul & Garcia-Romeu (2021) found that among 313 BIPOC respondents, naturalistic psychedelic use was associated with significant reductions in traumatic stress, depression, and anxiety symptoms related to racism — suggesting potential therapeutic relevance for populations currently underrepresented in clinical research.

### 13.2 Structural Barriers

Current barriers to equitable access include: high treatment costs (an estimated $5,000–$15,000 per treatment course), geographic concentration of treatment centers, lack of culturally competent therapist training, and the socioeconomic profile required to participate in clinical trials (flexibility, transportation, stable housing). MAPP2's deliberate recruitment of a racially diverse cohort (33.7% non-White) represents an important step, but systematic efforts to include underrepresented populations across all psychedelic trials remain insufficient.

---

## 14. Ethical Considerations in Psychedelic Therapy

### 14.1 Vulnerability and Boundary Violations

Meikle et al. (2024) argued that sexual abuse in psychedelic therapy is a structural — not episodic — problem, driven by features that increase patient vulnerability: altered consciousness, amplified suggestibility, intense attachment/transference, and the use of therapeutic touch. McNamee et al. (2023) documented cases from MDMA Phase 2 trials in which therapists physically restrained, cuddled, and kissed a participant on camera, and identified systemic failures in oversight including overly flexible protocols and "overcompliance" (therapists encouraging exclusively positive interpretation of experiences).

### 14.2 Therapist Training Standards

Brennan & Belser (2022) introduced EMBARK, a transdiagnostic, trans-drug model for psychedelic-assisted psychotherapy outlining six clinical domains for therapist competency. Brennan et al. (2025) described iterative development of the EMBARK training program, with the latest iteration (EMBARKCT) incorporating AI-assisted supervision monitoring. Standardized, competency-based training that includes ethics education and boundary violation prevention is essential for responsible clinical implementation.

### 14.3 Safety Guidelines

Johnson et al. (2008) published foundational safety guidelines identifying core safeguards: thorough psychiatric screening (including family history of psychosis), trained interpersonal support, controlled physical environment, preparation sessions, and integration follow-up. These guidelines have been adopted as the standard framework across all major research programs.

---

## 15. Microdosing: Placebo or Promise?

The microdosing literature provides an important counterpoint to the high-dose therapeutic paradigm.

**Szigeti et al. (2021)** conducted the largest placebo-controlled microdosing trial (N=191 completers) using a self-blinding citizen-science design. All psychological outcomes improved from baseline for both microdose and placebo groups, with **no significant between-group differences**. The authors concluded that anecdotal benefits of microdosing can be explained by the placebo effect.

**Cavanna et al. (2022)** — Double-blind, placebo-controlled RCT (N=34) of 0.5g dried psilocybin mushrooms found no significant effects on divergent or convergent thinking vs. placebo. **Polito & Liknaitzky (2024)** systematically reviewed 19 placebo-controlled microdosing studies and found changes in neurobiology and physiology relative to placebo but no lasting effects on mood, cognition, or creativity from repeated administration.

**Mueller et al. (2025)** — A randomized clinical trial of repeated low-dose LSD for ADHD treatment in adults found the intervention was safe but failed to demonstrate efficacy vs. placebo.

The contrast between null microdosing results and robust high-dose therapeutic effects supports the hypothesis that a full psychedelic experience — with its associated neuroplasticity, psychological insight, and mystical/peak experiences — is necessary for therapeutic benefit, rather than subtle pharmacological modulation.

---

## 16. International Regulatory Landscape

### 16.1 Australia

Australia became the first country to formally reschedule psilocybin and MDMA for therapeutic use, effective July 1, 2023. Under the Authorised Prescriber Scheme, authorized psychiatrists may prescribe psilocybin for TRD and MDMA for treatment-resistant PTSD (Ritchie et al., 2023). Access requires TGA approval, human research ethics committee endorsement, and demonstrated training.

### 16.2 United States: State-Level Frameworks

**Oregon Measure 109** (passed November 2020): Created the first state-regulated psilocybin services framework. Licensed service centers began serving clients in June 2023. No medical referral required; adults 21+ with mandatory preparation and integration sessions.

**Colorado Proposition 122** (passed November 2022): Decriminalized personal use of psilocybin, psilocin, DMT, ibogaine, and mescaline for adults 21+. Created regulated "healing centers" for supervised psilocybin administration. First state-regulated session conducted June 2025. Possible expansion to DMT, ibogaine, and mescaline starting 2026.

### 16.3 Canada

Health Canada amended Food and Drug Regulations effective January 2022, allowing the Special Access Programme (SAP) to authorize access to restricted drugs including psilocybin and MDMA on a case-by-case basis. By February 2024: 176 Canadians authorized for psilocybin access (78% approval rate), 41 for MDMA.

### 16.4 Europe

The European Medicines Agency (2024) held a multi-stakeholder workshop and updated guidance on clinical investigation for depression to formally include psychedelics. Switzerland has maintained a limited medical use program since 2014, with >700 patients treated with MDMA, LSD, or psilocybin by 2024. Germany approved its first Compassionate Use Program for psilocybin in TRD. The Netherlands' scientific advisory group recommended MDMA-AT approval for PTSD (June 2024). The UK's Schedule 1 classification remains a significant research barrier.

---

## 17. Discussion

### 17.1 The Signal Is Real, but Attenuating with Rigor

The consistency of positive findings across multiple independent meta-analyses, conducted by different research groups using different methodologies, provides strong evidence that psilocybin and MDMA possess genuine therapeutic properties that exceed placebo effects. However, the trajectory from Phase 2 to Phase 3 results reveals important signal attenuation:

- **Phase 2 psilocybin for depression:** g = 0.89–2.5 (depending on comparator)
- **Phase 3 psilocybin for TRD (COMP360):** ΔMADRS = -3.6 to -3.8 points

This pattern mirrors the broader landscape of psychiatric drug development, where initial trials overestimate effects due to smaller samples, less representative populations, and stronger allegiance effects (Turner et al., 2008). The Phase 3 effect sizes, while statistically significant, are in the range of esketamine's TRANSFORM-2 trial (ΔMADRS = -4.0 points) — meaningful but not the transformative paradigm shift that early Phase 2 data suggested.

### 17.2 The Comparative Landscape

Synthesizing across all evidence reviewed, the comparative efficacy picture is nuanced:

**For depression:**
- Psilocybin's pooled meta-analytic effect (g ≈ 0.66–0.89 vs. placebo) is 2–3× larger than SSRIs (g ≈ 0.30) and comparable to CBT (g ≈ 0.65–0.75)
- Psilocybin's onset (days) is substantially faster than SSRIs (weeks) and CBT (weeks-months)
- Psilocybin requires 1–2 sessions vs. daily SSRI administration or 12–20 CBT sessions
- Long-term data suggest durability of 6–12 months (Gukasyan et al., 2022; Goodwin et al., 2025), though this requires confirmation in larger cohorts

**For PTSD:**
- MDMA-AT effect sizes (d = 0.7–0.91) exceed SSRIs (d ≈ 0.3–0.4) by 2–3 fold
- MDMA-AT is comparable to trauma-focused psychotherapy (PE: g = 1.08) but requires only 3 sessions vs. 12–16
- MDMA-AT achieves higher remission rates (67–71%) than any conventional treatment

**For substance use disorders:**
- Psilocybin shows promising signals (d = 0.62 for AUD; 60–80% abstinence for TUD)
- These effects compare favorably to conventional pharmacotherapy (acamprosate NNT = 12; varenicline OR = 2.88)
- The evidence base remains thin and requires randomized confirmation

**For cancer-related distress:**
- The strongest case for any psychedelic, with exceptionally large effect sizes (d = 1.3–3.4) and extraordinary durability (4.5+ years)
- No conventional treatment approaches this efficacy for existential distress in terminal illness

### 17.3 Mechanistic Plausibility

The neurobiological evidence provides a credible mechanistic framework. The convergence of 5-HT2A agonism, DMN modulation, and psychoplastogen-mediated neuroplasticity (Olson, 2018; Shao et al., 2021; De Vos et al., 2021) offers a coherent account of how a single or small number of dosing sessions might produce sustained therapeutic effects. Daws et al. (2022) demonstrated that psilocybin's mechanism (increased global brain integration) is fundamentally distinct from SSRIs (serotonin reuptake inhibition), suggesting these are complementary rather than competing approaches.

The null microdosing results (Szigeti et al., 2021) and the Hesselgrave et al. (2021) dissociation of therapeutic neuroplasticity from hallucinogenic experience raise fascinating questions about whether the subjective experience is necessary, merely correlated, or partly separable from the therapeutic mechanism. Olson's (2022) work on non-hallucinogenic psychoplastogens (tabernanthalog) may eventually clarify this question.

### 17.4 The Regulatory Path Forward

The FDA's rejection of MDMA-AT highlights the tension between promising clinical data and methodological standards. For psilocybin, the COMP360 Phase 3 results (COMP005, COMP006) have met their primary endpoints, and regulatory filing is anticipated. LSD (MindMed's MM120) received Breakthrough Therapy Designation for GAD. The short-acting tryptamines (SPL026, GH001) are advancing rapidly, with the advantage of 20–60 minute psychedelic experiences that may be more practical for clinical implementation than 6–8 hour psilocybin sessions.

Australia's pioneering rescheduling (2023), Oregon's psilocybin services framework, and Colorado's Natural Medicine Health Act represent alternative regulatory models that may provide real-world evidence to complement clinical trial data.

### 17.5 Toward Responsible Integration

Implementation requires:

- **Novel clinical infrastructure:** Dedicated treatment spaces, trained therapist pairs, standardized training programs (Brennan & Belser, 2022)
- **Ethical safeguards:** Robust protocols to prevent boundary violations, independent oversight, therapist accountability (McNamee et al., 2023; Meikle et al., 2024)
- **Equity and access:** Deliberate inclusion of BIPOC communities in research and treatment (George et al., 2020; Michaels et al., 2018)
- **Cost management:** Economic models suggest favorable cost-effectiveness (Marseille et al., 2022), but treatment costs of $5,000–$15,000 must be managed through insurance coverage and scalable delivery models
- **Long-term pharmacovigilance:** Systematic monitoring for rare adverse events including HPPD, cardiovascular effects with repeated dosing, and psychological harms
- **Integration with existing care:** Psychedelic-assisted therapy should complement, not replace, evidence-based treatments. Goodwin et al. (2023) demonstrated that psilocybin can be safely administered as adjunct to ongoing SSRI treatment

---

## 18. Conclusions

The meta-analytic evidence synthesized in this expanded review demonstrates that:

1. **Psilocybin-assisted therapy produces medium-to-large effect sizes for depression** (g = -0.66 to -1.49 vs. placebo; Phase 3 ΔMADRS = -3.6 to -3.8), substantially exceeding SSRIs (g ≈ 0.30) with dramatically faster onset (days vs. weeks) and requiring only 1–2 sessions. Long-term data suggest durability of 6–12+ months. NNT (5) compares favorably to esketamine (7).

2. **MDMA-assisted therapy produces large effect sizes for PTSD** (d = 0.7–0.91), exceeding FDA-approved pharmacotherapy by 2–3 fold and achieving diagnostic remission rates of 67–71%. Long-term follow-up suggests durability, though the evidence base is complicated by data retraction and the FDA's 2024 rejection.

3. **LSD-assisted therapy shows large effect sizes for anxiety** (d = -1.18) and depression (d = -1.1), with FDA Breakthrough Therapy Designation for GAD (MindMed MM120). **Short-acting tryptamines** (DMT, 5-MeO-DMT) show remarkable early results with the practical advantage of brief session durations.

4. **Psilocybin for cancer-related distress** represents the strongest evidence for any psychedelic, with exceptionally large effect sizes (d = 1.3–3.4), extraordinary durability (4.5+ years), and no comparable conventional alternative.

5. **Preliminary evidence supports psilocybin for substance use disorders** (AUD, TUD), with effects that appear to exceed or match conventional pharmacotherapy, though randomized confirmation is needed. Ibogaine shows promising observational evidence for opioid dependence and trauma, with major clinical trials underway.

6. **Emerging indications** — OCD, eating disorders, cluster headache — show early promise, with the first controlled trials yielding positive preliminary results.

7. **The safety profile in controlled settings is favorable**, with rare serious adverse events, no reported cases of persistent psychosis, HPPD, or suicide in modern clinical research involving thousands of participants. The side-effect burden compares favorably to chronic SSRI use.

8. **Cost-effectiveness models** suggest psychedelic-assisted therapy could generate substantial healthcare savings, with ICER estimates ranging from $2,384/QALY (MDMA for PTSD) to $117,517/QALY (psilocybin for TRD).

9. **Significant methodological limitations persist**, including functional unblinding, effect size attenuation from Phase 2 to Phase 3, high risk of bias, limited diversity in trial populations, ethical concerns regarding therapist conduct, and the regulatory challenges of evaluating combined drug-therapy interventions.

10. **The data clearly suggest that the psychedelic pharmacopeia offers efficacy that matches or exceeds conventional prophylaxis across multiple psychiatric conditions**, with the distinguishing feature of achieving these effects in 1–3 sessions rather than through chronic daily administration. Whether this translates to a paradigm shift in clinical psychiatry depends on the next generation of confirmatory trials, regulatory decisions, and implementation frameworks that prioritize safety, equity, and rigorous evidence.

---

## References

1. Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. *Neuroscience & Biobehavioral Reviews*, 113, 179–189.
2. Hultgren, J., Hafsteinsson, M. H., & Gruneau Brulin, J. (2025). A dose of therapy with psilocybin—A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy. *General Hospital Psychiatry*, 96, 234–243.
3. Agin-Liebes, G. I., et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. *Journal of Psychopharmacology*, 34(2), 155–166.
4. Keighley, E. E., Abo Hamza, E., Bedewy, D. A., Nalla, S., & Moustafa, A. A. (2025). A systematic review and meta-analysis investigating the efficacy of various psychedelic drugs for the treatment of substance use disorder. *Healthcare*, 13(21), 2668.
5. Wong, S., Kwan, A. T. H., Teopiz, K. M., et al. (2024). A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. *Journal of Affective Disorders*, 350, 698–705.
6. Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. *Journal of Psychopharmacology*, 30(12), 1279–1295.
7. Bogenschutz, M. P., et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. *JAMA Psychiatry*, 79(10), 953–962.
8. Borgogna, N. C., et al. (2025). Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. *Psychopharmacology*, 242, 2139–2157.
9. Rieser, N. M., et al. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. *eClinicalMedicine*.
10. Bradley, R., Greene, J., Russ, E., Dutra, L., & Westen, D. (2005). A multidimensional meta-analysis of psychotherapy for PTSD. *American Journal of Psychiatry*, 162(2), 214–227.
11. Breeksema, J. J., et al. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. *Journal of Psychopharmacology*, 36(10), 1100–1117.
12. Brennan, W., & Belser, A. B. (2022). Models of psychedelic-assisted psychotherapy: A contemporary assessment and an introduction to EMBARK. *Frontiers in Psychology*, 13, 866018.
13. Brennan, W., et al. (2025). Psychedelic training program development: Lessons from the evolution of the EMBARK program. *Frontiers in Psychology*, 16, 1637887.
14. Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013). Pharmacological interventions for smoking cessation: An overview and network meta-analysis. *Cochrane Database of Systematic Reviews*, 2013(5), CD009329.
15. Carhart-Harris, R. L., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences*, 109(6), 2138–2143.
16. Carhart-Harris, R. L., et al. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. *Frontiers in Human Neuroscience*, 8, 20.
17. Carhart-Harris, R. L., et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Scientific Reports*, 7, 13187.
18. Carhart-Harris, R. L., et al. (2021). Trial of psilocybin versus escitalopram for depression. *New England Journal of Medicine*, 384(15), 1402–1411.
19. Cavanna, F., et al. (2022). Microdosing with psilocybin mushrooms: A double-blind placebo-controlled study. *Translational Psychiatry*, 12, 307.
20. Avanceña, A. L. V., Vuong, L., Kahn, J. G., & Marseille, E. (2025). Psilocybin-assisted therapy for treatment-resistant depression in the US: A model-based cost-effectiveness analysis. *Translational Psychiatry*, 15, 330.
21. Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. *The Lancet*, 391(10128), 1357–1366.
22. Cuijpers, P., et al. (2013). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. *Canadian Journal of Psychiatry*, 58(7), 376–385.
23. Cuijpers, P., et al. (2023). Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression. *World Psychiatry*, 22(1), 105–115.
24. Fang, S., Yang, X., & Zhang, W. (2024). Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of RCTs. *Frontiers in Psychiatry*, 15, 1359088.
25. Davis, A. K., et al. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. *JAMA Psychiatry*, 78(5), 481–489.
26. Daws, R. E., et al. (2022). Increased global integration in the brain after psilocybin therapy for depression. *Nature Medicine*, 28(4), 844–851.
27. De Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021). Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. *Frontiers in Psychiatry*, 12, 724606.
28. Dyck, E. (2005). Flashback: Psychiatric experimentation with LSD in historical perspective. *Canadian Journal of Psychiatry*, 50(7), 381–388.
29. Erritzoe, D., et al. (2024). Effect of psilocybin versus escitalopram on depression symptom severity: Observational 6-month follow-up of a phase 2 trial. *eClinicalMedicine*, 76, 102799.
30. Erritzoe, D., et al. (2026). A short-acting psychedelic intervention for major depressive disorder: A phase IIa randomized placebo-controlled trial. *Nature Medicine*.
31. Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Current Drug Abuse Reviews*, 7(3), 157–164.
32. Gattuso, J. J., et al. (2023). Default mode network modulation by psychedelics: A systematic review. *International Journal of Neuropsychopharmacology*, 26(3), 155–188.
33. George, J. R., Michaels, T. I., Sevelius, J., & Williams, M. T. (2020). The psychedelic renaissance and the limitations of a White-dominant medical framework. *Journal of Psychedelic Studies*, 4(1), 4–15.
34. Goodwin, G. M., et al. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. *New England Journal of Medicine*, 387(18), 1637–1648.
35. Goodwin, G. M., et al. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. *Neuropsychopharmacology*, 48, 1492–1499.
36. Goodwin, G. M., et al. (2025a). Results from a long-term observational follow-up study of a single dose of psilocybin for TRD. *Journal of Clinical Psychiatry*, 86(1), 24m15449.
37. Goodwin, G. M., et al. (2025b). Single treatment with MM120 (lysergide) in generalized anxiety disorder: A randomized clinical trial. *JAMA*, 334(15), 1358–1372.
38. Griffiths, R. R., et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, 187(3), 268–283.
39. Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. *Journal of Psychopharmacology*, 30(12), 1181–1197.
40. Gukasyan, N., et al. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. *Journal of Psychopharmacology*, 36(2), 151–158.
41. Halpern, J. H., Lerner, A. G., & Passie, T. (2018). A review of hallucinogen persisting perception disorder (HPPD). *Current Topics in Behavioral Neurosciences*, 36, 333–360.
42. Hamilton, J. P., et al. (2015). Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. *Biological Psychiatry*, 78(4), 224–230.
43. Hesselgrave, N., et al. (2021). Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. *Proceedings of the National Academy of Sciences USA*, 118(17), e2022489118.
44. Hinkle, J. T., et al. (2024). Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. *JAMA Psychiatry*, 81(12), 1225–1235.
45. Holze, F., et al. (2023). Lysergic acid diethylamide–assisted therapy in patients with anxiety: A randomized, double-blind, placebo-controlled phase II study. *Biological Psychiatry*, 93(3), 215–223.
46. Holze, F., et al. (2024). LSD-assisted therapy in patients with anxiety: Open-label prospective 12-month follow-up. *The British Journal of Psychiatry*, 225(3), 362–370.
47. Muller, F., et al. (2025). Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. *Med*, doi: 10.1016/j.medj.2025.100725.
48. Mueller, L., Santos de Jesus, J., Schmid, Y., et al. (2025). Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: A randomized clinical trial. *JAMA Psychiatry*, 82(6), 555–562.
49. Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. *Journal of Psychopharmacology*, 22(6), 603–620.
50. Johnson, M. W., et al. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology*, 28(11), 983–992.
51. Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. *American Journal of Drug and Alcohol Abuse*, 43(1), 55–60.
52. Jonas, D. E., et al. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings. *JAMA*, 311(18), 1889–1900.
53. Knatz Peck, S., et al. (2023). Psilocybin therapy for females with anorexia nervosa: A phase 1, open-label feasibility study. *Nature Medicine*, 29, 1947–1953.
54. Ko, K., et al. (2023). Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. *Journal of Affective Disorders*, 322, 194–204.
55. Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of RCTs. *Journal of Psychopharmacology*, 26(7), 994–1002.
56. Leucht, S., et al. (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: Review of meta-analyses. *British Journal of Psychiatry*, 200(2), 97–106.
57. Ly, C., et al. (2018). Psychedelics promote structural and functional neural plasticity. *Cell Reports*, 23(11), 3170–3182.
58. Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J. M., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022). Human cortical serotonin 2A receptor occupancy by psilocybin measured using [11C]MDL 100,907 dynamic PET. *Frontiers in Neuroergonomics*, 2, 784576.
59. Marseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R. (2020). The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. *PLOS ONE*, 15(10), e0239997.
60. Marseille, E., Mitchell, J. M., & Kahn, J. G. (2022a). Updated cost-effectiveness of MDMA-assisted therapy for PTSD: Findings from a phase 3 trial. *PLOS ONE*, 17(2), e0263252.
61. Marseille, E., Bertozzi, S. M., & Kahn, J. G. (2022b). The economics of psychedelic-assisted therapies: A research agenda. *Frontiers in Psychiatry*, 13, 1025726.
62. McCrone, P., et al. (2023). Cost-effectiveness of psilocybin-assisted therapy for severe depression: Exploratory findings from a decision analytic model. *Psychological Medicine*, 53(16), 7619–7626.
63. McIntyre, R. S., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion. *American Journal of Psychiatry*, 178(5), 383–399.
64. Alnefeesi, Y., Chen-Li, D., Krane, E., et al. (2022). Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. *Journal of Psychiatric Research*, 151, 693–709.
65. McNamee, S., Devenot, N., & Buisson, M. (2023). Studying harms is key to improving psychedelic-assisted therapy. *JAMA Psychiatry*, 80(5), 411–412.
66. Meikle, S., Carter, O., & Bedi, G. (2024). Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power. *Australian & New Zealand Journal of Psychiatry*, 58(2), 104–106.
67. Menon, V., et al. (2025). Randomized controlled trials of psilocybin-assisted therapy in the treatment of major depressive disorder. *Acta Psychiatrica Scandinavica*, 151(5), 557–571.
68. Metaxa, A. M., & Clarke, M. (2024). Efficacy of psilocybin for treating symptoms of depression: Systematic review and meta-analysis. *BMJ*, 385, e078084.
69. Michaels, T. I., et al. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. *BMC Psychiatry*, 18(1), 245.
70. Mitchell, J. M., et al. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. *Nature Medicine*, 27(6), 1025–1033.
71. Mitchell, J. M., et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. *Nature Medicine*, 29(10), 2473–2480.
72. Mithoefer, M. C., et al. (2013). Durability of improvement in PTSD symptoms and absence of harmful effects after MDMA-assisted psychotherapy: A prospective long-term follow-up study. *Journal of Psychopharmacology*, 27(1), 28–39.
73. Mithoefer, M. C., et al. (2019). MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 RCTs. *Psychopharmacology*, 236, 2735–2745. [**RETRACTED August 2024**]
74. Moreno, F. A., et al. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *Journal of Clinical Psychiatry*, 67(11), 1735–1740.
75. Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *American Journal of Drug and Alcohol Abuse*, 44(1), 37–46.
76. Olson, D. E. (2018). Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. *Journal of Experimental Neuroscience*, 12, 1179069518800508.
77. Olson, D. E. (2022). Biochemical mechanisms underlying psychedelic-induced neuroplasticity. *Biochemistry*, 61(3), 127–136.
78. Orsolini, L., et al. (2017). The "Endless Trip" among the NPS users: Psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. *Frontiers in Psychiatry*, 8, 240.
79. Ot'alora G, M., et al. (2018). 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic PTSD: A randomized phase 2 controlled trial. *Journal of Psychopharmacology*, 32(12), 1295–1307.
80. Palhano-Fontes, F., et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. *Psychological Medicine*, 49(4), 655–663.
81. Pellegrini, L., et al. (2025). Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder. *Comprehensive Psychiatry*, 142.
82. Polito, V., & Liknaitzky, P. (2024). Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. *Journal of Psychopharmacology*, 38(8), 701–711.
83. Powers, M. B., et al. (2010). A meta-analytic review of prolonged exposure for posttraumatic stress disorder. *Clinical Psychology Review*, 30(6), 635–641.
84. Preller, K. H., et al. (2017). The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. *Current Biology*, 27(3), 451–457.
85. Raison, C. L., et al. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. *JAMA*, 330(9), 843–853.
86. Reckweg, J. T., et al. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. *Frontiers in Psychiatry*, 14, 1133414.
87. Ritchie, O. D., Donley, C. N., & Ritchie, G. D. (2023). From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia. *Drug Science, Policy and Law*, 9.
88. Ching, T. H. W., et al. (2024). Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of OCD: Protocol for a randomized, waitlist-controlled trial. *Frontiers in Psychiatry*, 14, 1278823.
89. Rosenblat, J. D., et al. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses. *Med*, 5(3), 190–200.
90. Ross, S., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. *Journal of Psychopharmacology*, 30(12), 1165–1180.
91. Rouaud, A., Calder, A. E., & Hasler, G. (2024). Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy. *Journal of Psychopharmacology*, 38(3), 217–224.
92. Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *American Journal of Psychiatry*, 163(11), 1905–1917.
93. Sanches, R. F., et al. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. *Journal of Clinical Psychopharmacology*, 36(1), 77–81.
94. Schindler, E. A. D., et al. (2022). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache. *Headache*, 62(10), 1383–1394.
95. Schindler, E. A. D., et al. (2024). Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase. *Journal of the Neurological Sciences*, 460, 122993.
96. Schlag, A. K., et al. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. *Journal of Psychopharmacology*, 36(3), 258–272.
97. Shahrour, G., et al. (2024). MDMA-assisted psychotherapy for the treatment of PTSD: A systematic review and meta-analysis of RCTs. *Neuropsychopharmacology Reports*, 44(4), 672–681.
98. Shao, L.-X., et al. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. *Neuron*, 109(16), 2535–2544.
99. Sloshower, J., et al. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. *Journal of Psychopharmacology*, 37(7), 698–706.
100. Stanicic, F., et al. (2025). MDMA-assisted therapy and current treatment options for chronic, treatment-resistant PTSD: Systematic literature review. *PLOS ONE*, 20(7), e0327778.
101. Stein, D. J., et al. (2006). Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database of Systematic Reviews*.
102. Sewell, R. A., Halpern, J. H., & Pope, H. G. Jr. (2006). Response of cluster headache to psilocybin and LSD. *Neurology*, 66(12), 1920–1922.
103. Swieczkowski, D., et al. (2025). Efficacy and safety of psilocybin in the treatment of MDD: A dose-response network meta-analysis. *Psychiatry Research*, 344, 116337.
104. Wsol, A. (2023). Cardiovascular safety of psychedelic medicine: Current status and future directions. *Pharmacological Reports*, 75(6), 1362–1380.
105. Szigeti, B., et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. *eLife*, 10, e62878.
106. Thomas, G., et al. (2013). Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. *Current Drug Abuse Reviews*, 6(1), 30–42.
107. Thrul, J., & Garcia-Romeu, A. (2021). Whitewashing psychedelics: Racial equity in the emerging field of psychedelic-assisted mental health research and treatment. *Drugs: Education, Prevention and Policy*, 28(3), 211–214.
108. Turner, E. H., et al. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *New England Journal of Medicine*, 358(3), 252–260.
109. Van der Meer, P. B., et al. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. *Frontiers in Psychiatry*, 14, 1134454.
110. Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. *Nature Reviews Neuroscience*, 21(11), 611–624.
111. Von Rotz, R., et al. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. *eClinicalMedicine*, 56, 101809.
112. WHO (2023). *Depressive disorder (depression).* World Health Organization Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/depression
113. Wilkinson, S. T., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. *American Journal of Psychiatry*, 175(2), 150–158.
114. Williams, N. R., et al. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injuries. *Nature Medicine*, 30, 373–381.
115. Yang, J., et al. (2024). The efficacy and safety of MDMA-assisted psychotherapy for treatment of PTSD: A systematic review and meta-analysis from RCTs. *Psychiatry Research*, 339, 116043.
116. Yao, S., et al. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. *Psychiatry Research*, 335, 115886.
117. Yong, A. S. J., et al. (2025). Safety and efficacy of MDMA-assisted psychotherapy in PTSD: An overview of systematic reviews and meta-analyses. *Australian and New Zealand Journal of Psychiatry*.
118. Baum, D. (2016). Legalize it all: How to win the war on drugs. *Harper's Magazine*, April 2016.
119. Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: A multicriteria decision analysis. *The Lancet*, 376(9752), 1558–1565.
120. Grof, S. (1975). *Realms of the Human Unconscious: Observations from LSD Research*. New York: Viking Press.
121. Sessa, B. (2012). *The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society*. London: Muswell Hill Press.
122. Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. *Neuropharmacology*, 142, 200–218.
123. Nutt, D. J. (2009). Equasy — An overlooked addiction with implications for the current debate on drug harms. *Journal of Psychopharmacology*, 23(1), 3–5.
124. Marks, M., & Cohen, I. G. (2021). Psychedelic therapy: A roadmap for wider acceptance and utilization. *Nature Medicine*, 27(10), 1669–1671.
125. Hancock, G. (2015). *The Divine Spark: A Graham Hancock Reader — Psychedelics, Consciousness, and the Birth of Civilization*. Hay House.
126. Boire, R. G. (1999/2000). On cognitive liberty. *Journal of Cognitive Liberties*, 1(1), 7–13.
127. Carhart-Harris, R. L., & Nutt, D. J. (2014). Was it a vision or a waking dream? *Frontiers in Psychology*, 5, 255.
